Also brentuximab vedotin is recommended for use within the Cancer Drugs Fund as an option for treating CD30 positive Hodgkin lymphoma in adults, only if: they have relapsed or refractory disease after at least 2 previous therapies and they cannot have autologous stem cell transplant or multi-agent chemotherapy and the conditions of the managed access agreement are followed.